Bendamustine
From Wikipedia, the free encyclopedia
 |
|
|
Bendamustine
|
|
| Systematic (IUPAC) name | |
| 4-[5-[Bis(2-chloroethyl)amino]-1-methylbenzimidazol-2-yl]butanoic acid | |
| Identifiers | |
| CAS number | ? |
| ATC code | ? |
| PubChem | |
| Chemical data | |
| Formula | C16H21Cl2N3O2 |
| Mol. mass | 358.262 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Licence data |
|
| Pregnancy cat. |
D(US) |
| Legal status | |
| Routes | Intravenous |
Bendamustine (INN, tradenames Ribomustin and Treanda; also known as SDX-105) is a substance in the treatment of leukemia[1]. It belongs to the family of drugs called alkylating agents. It is also being studied for the treatment of sarcoma.[2]
[edit] History
Bendamustine received its first marketing approval in Germany, which is marketed under the tradename Ribomustin, by Astellas Pharma GmbH's licensee, Mundipharma International Corporation Limited, which it is indicated as a single-agent or in combination with other anti-cancer agents for indolent NHL, multiple myeloma, and CLL. SymBio Pharmaceuticals Ltd holds exclusive rights to develop and market bendamustine HCl in Japan and selected Asia Pacific Rim countries.
On March 20, 2008, Cephalon received approval from the United States Food and Drug Administration to market bendamustine in the US, where it is sold under the tradename Treanda.[3] Bendamustine is the first drug approved for patients with CLL in the US since 2001.
[edit] References
- ^ Kath R, Blumenstengel K, Fricke HJ, Höffken K (January 2001). "Bendamustine monotherapy in advanced and refractory chronic lymphocytic leukemia". J. Cancer Res. Clin. Oncol. 127 (1): 48–54. PMID 11206271.
- ^ Bagchi S (August 2007). "Bendamustine for advanced sarcoma". Lancet Oncol. 8 (8): 674. PMID 17726779.
- ^ Cephalon press release - Cephalon Receives FDA Approval for TREANDA, a Novel Chemotherapy for Chronic Lymphocytic Leukemia. Retrieved on 2008-03-23.
